Backers included Tensor Ventures, Lighthouse Ventures, BSV Ventures, Moondust Ventures, and 22 Hor Invest, as well as Tim Draper of Draper Associates.
The company intends to use the funds to expand operations and its R&D efforts.
Led by Kinga Matula, CEO, QurieGen develops QuRIE-seq, a platform providing patented single-cell technology that enhances the drug discovery and development process. It enables the decoding of cellular responses by simultaneously quantifying mRNA molecules, as well as hundreds of membrane proteins, intracellular proteins, and phosphoproteins.
“This is not just a milestone—it’s a moment that will accelerate our mission to build “Google Maps for cells”—a game-changing, AI-driven platform that will revolutionize oncology research and bring life-saving treatments to patients faster than ever before” wrote Kinga in a Linkedin post.
“This journey has been deeply personal. The past two years have shaped me as a scientist, innovator, and entrepreneur. From almost giving up in January last year, to meeting my incredible co-founder Maciej Jarzabąb (who, at QurieGen, has rightfully earned the title of Chief Dreaming Officer ), to meeting our other amazing team members, and working at Scope Fluidics alongside inspiring leaders and the Scope Discovery team—this year has been nothing short of a quantum leap” adds Kinga.
The company currently operates at the interface between the Netherlands and Poland, leveraging the scientific base in the Netherlands and the Polish technology ecosystem.
Curious to learn more? Enjoy our most recent Podcast interview with Kinga Matula.
